EVAX Evaxion Biotech
- 4.220
- +0.110+2.68%
- 4.220
- 0.0000.00%
Evaxion Biotech News
Express News | Evaxion Announces First Patient Completed Dosing With Personalized Cancer Vaccine EVX-01
Express News | Evaxion Biotech A/S - Favorable Safety Profile Confirmed
Express News | Evaxion Biotech A/S - Trial on Track for One-Year Clinical Efficacy Readout in Q3 2024
Express News | Evaxion Announces Phase 2 Clinical Trial Update: First Patient Completed Dosing With Personalized Cancer Vaccine Evx-01
European Equities Traded in the US as American Depositary Receipts Decline in Thursday Trading
European equities traded in the US as American depositary receipts were weaker Thursday morning, falling 0.91% to 1,353.49 on the S&P Europe Select ADR Index.
European Equities Traded in the US as American Depositary Receipts Trend Lower in Tuesday Trading
European equities traded in the US as American depositary receipts were trending moderately lower Tuesday morning, declining 0.49% to 1,372.87 on the S&P Europe Select ADR Index. From continental Euro
European Equities Traded in the US as American Depositary Receipts Open Week Higher in Monday Trading
European equities traded in the US as American depositary receipts opened the week in positive territory Monday morning, rising 0.50% to 1,380.48 on the S&P Europe Select ADR Index. From continental E
European Equities Traded in the US as American Depositary Receipts Higher in Friday Trading, Close Out Week Lower
European equities traded in the US as American depositary receipts were trending modestly higher Friday morning, rising 0.27% to 1,369.92 on the S&P Europe Select ADR Index. However, the gain isn't en
European Equities Traded in the US as American Depositary Receipts Trend Higher in Wednesday Trading
European equities traded in the US as American depositary receipts were trending higher late Wednesday morning, rising 0.52% to 1,375.67 on the S&P Europe Select ADR Index. From continental Europe, th
Evaxion Biotech A/S (NASDAQ:EVAX) Q4 2023 Earnings Call Transcript
Express News | HC Wainwright & Co. Reiterates Buy on Evaxion Biotech, Maintains $14 Price Target
Analysts Have Conflicting Sentiments on These Healthcare Companies: Evaxion Biotech (EVAX), 60 Degrees Pharmaceuticals, Inc. (SXTP) and Genprex (GNPX)
Earnings Call Summary | Evaxion Biotech(EVAX.US) Q4 2023 Earnings Conference
The following is a summary of the Evaxion Biotech A/S (EVAX) Q4 2023 Earnings Call Transcript:Financial Performance:Evaxion Biotech reported a net loss of $22.1 million in 2023, a slight reduction com
Sector Update: Health Care Stocks Slipping in Afternoon Trading
Health care stocks were retreating Tuesday afternoon, with the NYSE Health Care Index and the Health Care Select Sector SPDR Fund (XLV) each shedding 1.9%. The iShares Biotechnology ETF (IBB) fell 2.2
Evaxion's EVX-B1 Vaccine Shows Promising Protection Against Staph Infections in Preclinical Studies
Evaxion Biotech (EVAX) said Tuesday that three studies showed antigens from its preclinical EVX-B1 vaccine candidate significantly protected large, non-rodent animals against surgical site infections caused by Staphylococcus aureus.
12 Health Care Stocks Moving In Tuesday's Intraday Session
GainersNexalin Technology (NASDAQ:NXL) stock increased by 47.9% to $2.81 during Tuesday's regular session. The market value of their outstanding shares is at $20.4 million. MSP Recovery (NASDAQ:LIFW)
Evaxion Biotech Raised to Buy From Neutral by Ladenburg Thalmann
Evaxion Biotech Raised to Buy From Neutral by Ladenburg Thalmann
Express News | Ladenburg Thalmann Upgrades Evaxion Biotech to Buy, Announces $8 Price Target
Express News | Evaxion Biotech Concludes Large Non-rodent Animal Infection Studies, Testing Antigens From Evaxion's Preclinical EVX-b1 Vaccine Candidate Against Staphylococcus Aureus, Studies Showed EVX-b1 Antigens Significantly Reduced Disease Burden
Evaxion and Undisclosed Collaborator Announce Encouraging Results for EVX-B1 Vaccine Antigens Against Staphylococcus Aureus Infection
Evaxion Biotech A/S (NASDAQ: EVAX) ("Evaxion" or the "Company"), a clinical-stage TechBio company specializing in developing AI-Immunology powered vaccines, is pleased to announce the successful conclusion of a series of large non-rodent animal infection studies, testing antigens from Evaxion's preclinical EVX-B1 vaccine candidate against Staphylococcus aureus (S. aureus). In the animal studies, the EVX-B1 antigens significantly reduced disease burden.
Analysis
Price Target
No Data
